Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M 1 -acetylcholine receptor agonist: A randomized cross-over trial

Aims: HTL0009936 is a selective M 1 muscarinic receptor agonist in development for cognitive dysfunction in Alzheimer's disease. Safety, tolerability and pharmacokinetics and exploratory pharmacodynamic effects of HTL0009936 administered by con-tinuous IV infusion at steady state were investigated in elderly subjects with below average cognitive functioning (BACF). Methods: Part A was a four-treatment open label sequential study in healthy elderly investigating 10 – 83 mg HTL0009936 (IV) and a 24 mg HTL0009936 single oral dose. drug exposures. Therefore no clear conclusions can be made on pharmacodynamic effects of HTL0009936, although an effect on P300 is suggestive of central target engagement.

[1]  D. Erskine,et al.  Cholinergic muscarinic M1 and M4 receptors as therapeutic targets for cognitive, behavioural, and psychological symptoms in psychiatric and neurological disorders. , 2019, Drug discovery today.

[2]  J. V. van Gerven,et al.  A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development. , 2019, Journal of visualized experiments : JoVE.

[3]  P. Calabresi,et al.  Evidence of practice effect in CANTAB spatial working memory test in a cohort of patients with mild cognitive impairment , 2018, Applied neuropsychology. Adult.

[4]  J. V. van Gerven,et al.  An anti‐nicotinic cognitive challenge model using mecamylamine in comparison with the anti‐muscarinic cognitive challenge using scopolamine , 2017, British journal of clinical pharmacology.

[5]  J. Vilalta-Franch,et al.  Discontinuation, Efficacy, and Safety of Cholinesterase Inhibitors for Alzheimer’s Disease: a Meta-Analysis and Meta-Regression of 43 Randomized Clinical Trials Enrolling 16 106 Patients , 2017, The international journal of neuropsychopharmacology.

[6]  G. Groeneveld,et al.  Measuring blood-brain barrier penetration using the NeuroCart, a CNS test battery. , 2016, Drug discovery today. Technologies.

[7]  A. Maelicke,et al.  First in human study with a prodrug of galantamine: Improved benefit-risk ratio? , 2016, Alzheimer's & dementia.

[8]  G. Kaubrys,et al.  Selective Ability of Some CANTAB Battery Test Measures to Detect Cognitive Response to a Single Dose of Donepezil in Alzheimer Disease , 2015, Medical science monitor : international medical journal of experimental and clinical research.

[9]  D. Salisbury,et al.  Mismatch Negativity (MMN) as an Index of Cognitive Dysfunction , 2014, Brain Topography.

[10]  W. Riedel.  Preventing cognitive decline in preclinical Alzheimer's disease. , 2014, Current opinion in pharmacology.

[11]  P. Conn,et al.  Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer’s disease and schizophrenia , 2014, Neuropsychiatric disease and treatment.

[12]  Craig W Lindsley,et al.  Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease. , 2013, Drug discovery today.

[13]  E. Bullmore,et al.  The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction. , 2013, The international journal of neuropsychopharmacology.

[14]  S. Gau,et al.  Rapid visual information processing as a cognitive endophenotype of attention deficit hyperactivity disorder , 2013, Psychological Medicine.

[15]  M. Sabbagh,et al.  Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer’s disease , 2011, Acta Neuropathologica.

[16]  T. Suhara,et al.  Estimation of Plasma IC50 of Donepezil for Cerebral Acetylcholinesterase Inhibition in Patients With Alzheimer Disease Using Positron Emission Tomography , 2010, Clinical neuropharmacology.

[17]  D. Galimberti,et al.  Treatment of Alzheimer's disease: symptomatic and disease-modifying approaches. , 2010, Current aging science.

[18]  Seung-Schik Yoo,et al.  Altered Verbal Working Memory Process in Patients with Alzheimer’s Disease , 2008, Neuropsychobiology.

[19]  R. Dolan,et al.  Cholinesterase inhibition modulates visual and attentional brain responses in Alzheimer's disease and health. , 2008, Brain : a journal of neurology.

[20]  Christopher J Langmead,et al.  Muscarinic acetylcholine receptors as CNS drug targets. , 2008, Pharmacology & therapeutics.

[21]  J. Polich.  Updating P300: An integrative theory of P3a and P3b , 2007, Clinical Neurophysiology.

[22]  R. Berecz,et al.  Automated Neuropsychological Test Battery (CANTAB) in mild cognitive impairment and in Alzheimer's disease , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[23]  L. Candelise,et al.  Galantamine for Alzheimer’s Disease and Mild Cognitive Impairment , 2007, Neuroepidemiology.

[24]  Philip D. Harvey,et al.  Effects of rivastigmine on cognitive function in patients with traumatic brain injury , 2006, Neurology.

[25]  Stephen M. Rao,et al.  Functional magnetic resonance imaging response to increased verbal working memory demands among patients with multiple sclerosis , 2006, Human brain mapping.

[26]  Michael D Twa,et al.  Estimation of pupil size by digital photography , 2004, Journal of cataract and refractive surgery.

[27]  F Barkhof,et al.  Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer’s disease , 2002, Journal of neurology, neurosurgery, and psychiatry.

[28]  E. Feigl,et al.  Altered cardiovascular responses in mice lacking the M(1) muscarinic acetylcholine receptor. , 2002, The Journal of pharmacology and experimental therapeutics.

[29]  R. Koeppe,et al.  Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex , 2000, Annals of neurology.

[30]  K. Kameyama,et al.  Alterations of muscarinic acetylcholine receptor subtypes in diffuse Lewy body disease: relation to Alzheimer’s disease , 1999, Journal of neurology, neurosurgery, and psychiatry.

[31]  J. Gerven,et al.  The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation , 1999, Journal of psychopharmacology.

[32]  N. Birdsall,et al.  International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. , 1998, Pharmacological reviews.

[33]  Gwenn S. Smith,et al.  Physostigmine Reversal of Scopolamine-Induced Hypofrontality , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[34]  K. Davis.  Cholinesterase Inhibitors in Alzheimer's Disease , 1994, Neuropsychopharmacology.

[35]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[36]  H. Schoemaker,et al.  A comparison of the sensitivities of adaptive tracking, eye movement analysis, and visual analog lines to the effects of incremental doses of temazepam in healthy volunteers , 1991, Clinical pharmacology and therapeutics.

[37]  E. Donchin,et al.  P300 and recall in an incidental memory paradigm. , 1986, Psychophysiology.

[38]  D. Mash,et al.  Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. , 1985, Science.

[39]  R G Borland,et al.  Visual motor co-ordination and dynamic visual acuity. , 1984, British journal of clinical pharmacology.

[40]  R. Bartus,et al.  The cholinergic hypothesis of geriatric memory dysfunction. , 1982, Science.

[41]  J. Coyle,et al.  Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis , 1981, Annals of neurology.

[42]  Brenda Milner,et al.  Visually-guided maze learning in man: effects of bilateral hippocampal, bilateral frontal, and unilateral cerebral lesions , 1965 .

[43]  Jennifer H Barnett,et al.  The Paired Associates Learning (PAL) Test: 30 Years of CANTAB Translational Neuroscience from Laboratory to Bedside in Dementia Research. , 2016, Current topics in behavioral neurosciences.

[44]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[45]  I. Hindmarch,et al.  The leeds sleep evaluation questionnaire in psychopharmacological investigations—a review , 2004, Psychopharmacology.

[46]  Christiane,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2004, Journal international de bioethique = International journal of bioethics.

[47]  S. Eckstein.  Ethical principles for medical research involving human subjects. , 2001, European journal of emergency medicine : official journal of the European Society for Emergency Medicine.